Chicoric Acid

Chicoric Acid

SCHEMBL961606

O=C(C=Cc1ccc(O)c(O)c1)OC(C(=O)O)C(OC(=O)C=Cc1ccc(O)c(O)c1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 1.00
TDP1 Q9NUW8 6/20 1.00
ALOX15 P16050 3/20 1.00
TP53 P04637 2/20 1.00
SRC P12931 2/20 0.84
APP P05067 8/20 0.65
KDM4E B2RXH2 6/20 0.65
TTR P02766 6/20 0.65
MAPT P10636 5/20 0.65
HPGD P15428 4/20 0.65
AKR1B1 P15121 4/20 0.65
POLB P06746 3/20 0.65
GAA P10253 3/20 0.65
RECQL P46063 2/20 0.65
MMP1 P03956 2/20 0.65
THRB P10828 2/20 0.65
APEX1 P27695 2/20 0.65
CYP1A2 P05177 2/20 0.65
LCK P06239 2/20 0.65
FYN P06241 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chicoric Acid SCHEMBL13772650 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL30518333 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL964775 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL29349701 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL30995918 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL730803 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL29385936 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL963407 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL21176639 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL15532218 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-11701400-B2 Steviol glycoside compositions with reduced surface tension CARGILL, INCORPORATED (US) 2023-07-18 US claimed
US-20210298243-A1 UV-B INDUCED PLANT PATHOGEN RESISTANCE BIOLUMIC LIMITED (NZ) 2021-09-30 US claimed
EP-3876697-A2 UV-B INDUCED PLANT PATHOGEN RESISTANCE Biolumic Limited (NZ) 2021-09-15 EP claimed
CN-113271764-A UV-B induced resistance to plant pathogens 拜欧卢米克有限公司 2021-08-17 CN claimed
US-20200260767-A1 READILY DISSOLVABLE STEVIOL GLYCOSIDE COMPOSITIONS CARGILL, INCORPORATED (US) 2020-08-20 US claimed
EP-3691468-A1 READILY DISSOLVABLE STEVIOL GLYCOSIDE COMPOSITIONS Cargill, Incorporated (US) 2020-08-12 EP claimed
EP-3691466-A1 STEVIOL GLYCOSIDE COMPOSITIONS WITH REDUCED SURFACE TENSION Cargill, Incorporated (US) 2020-08-12 EP claimed
CN-111315234-A Easily soluble steviol glycoside compositions 嘉吉公司 2020-06-19 CN claimed
CN-111295097-A Steviol glycoside compositions with reduced surface tension 嘉吉公司 2020-06-16 CN claimed
US-6946490-B2 Antimicrobial treatment for herpes simplex virus and other infectious diseases MCGINLEY PARTNERS, LLC (US) 2005-09-20 US claimed
US-20050026902-A1 Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents PHARMACIA CORPORATION 2005-02-03 US claimed
EP-0918458-A4 ANTIMICROBIAL TREATMENT FOR HERPES SIMPLEX VIRUS AND OTHER INFECTIOUS DISEASES SQUIRES MERYL (US) 2004-01-02 EP claimed
US-20030104082-A1 Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases MCGINLEY PARTNERS, LLC (US) 2003-06-05 US claimed
US-20030099726-A1 Antimicrobial treatment for herpes simplex virus and other infectious diseases MCGINLEY PARTNERS, LLC (US) 2003-05-29 US claimed
US-20020187207-A1 Method for extracting, fractionating and purifying polyphenolic compounds originating from fresh plant sorting deviations using a high adsorption and elution performance resin INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE INRA 2002-12-12 US claimed
US-6355684-B1 AQUEOUS BENZALKONIUM CHLORIDE, ECHINACEA AND ANTIMICROBIAL ISOLATES; VIRICIDES FOR PAPILLOMA, VARICELLA-ZOSTER, AND CYTOMEGALO VIRUSE; HIGH SPEED ANALGESIC; HEALING OF LESIONS; TOPICAL ADMINISTERING Squires, Meryl J. 2002-03-12 US claimed
US-6350784-B1 PHYTOCHEMICALS, SURFACTANT, FOLIC ACID, Squires, Meryl J. 2002-02-26 US claimed
EP-0918458-A1 ANTIMICROBIAL TREATMENT FOR HERPES SIMPLEX VIRUS AND OTHER INFECTIOUS DISEASES Squires, Meryl (US) 1999-06-02 EP claimed
WO-1998011778-A1 ANTIMICROBIAL TREATMENT FOR HERPES SIMPLEX VIRUS AND OTHER INFECTIOUS DISEASES SQUIRES MERYL (US) 1998-03-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030099726-A1 Antimicrobial treatment for herpes simplex virus and other infectious diseases KCNJ11, KCNJ1, TRPA1 HSD17B10 2936/4885TDP1 3883/4885ALOX15 2782/4885
US-11701400-B2 Steviol glycoside compositions with reduced surface tension STT3A, SIGLEC7, STT3B HSD17B10 473/4885TDP1 1789/4885ALOX15 4388/4885
US-20020187207-A1 Method for extracting, fractionating and purifying polyphenolic compounds originating from fresh plant sorting deviations using a high adsorption and elution performance resin BROX, HPD, VPS28 HSD17B10 2469/4885TDP1 2564/4885ALOX15 3203/4885
US-20030104082-A1 Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases CD14, CD59, SLC19A1 HSD17B10 3387/4885TDP1 4355/4885ALOX15 1638/4885
US-20050026902-A1 Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents PTGS2, PTGS1, PTGES2 HSD17B10 314/4885TDP1 1351/4885ALOX15 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.